A 74-year-old woman with osteoporosis and chronic kidney disease (eGFR 35 mL/min/1.73m²) presents with worsening lower back pain for three weeks. Vital signs: BP 138/82, HR 78, RR 16, Temp 37°C, SpO2 98%. Recent DEXA scan shows a lumbar spine T-score of −2.8. Serum calcium is 9.1 mg/dL. She denies fever or focal neurologic symptoms. Physical exam reveals midline lumbar tenderness without paraspinal spasm. Previously taking oral bisphosphonate therapy, she is now switched to a monoclonal antibody that inhibits osteoclast activation by neutralizing RANK ligand. Which drug was prescribed?
- A)Teriparatide
- B)Alendronate
- C)Raloxifene
- D)DenosumabGABARITO
- E)Calcitonin
Explicação
Denosumab is a monoclonal antibody against RANKL, so it suppresses osteoclast differentiation and activity. That antiresorptive mechanism makes it useful in osteoporosis, though hypocalcemia and osteonecrosis of the jaw are important adverse effects. Ver explicação completa e trilha adaptativa →